PolyPeptide Group Ltd header image

PolyPeptide Group Ltd

PPGN

Equity

ISIN CH1110760852 / Valor 111076085

SIX Swiss Exchange (2025-11-21)

CHF 23.92+2.38%

PolyPeptide Group Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

PolyPeptide Group Ltd is a Contract Development and Manufacturing Organization (CDMO) that specializes in the development and production of active pharmaceutical ingredients (APIs) for both proprietary and generic drugs. The company collaborates with pharmaceutical and biotechnology firms to support the creation and manufacturing processes of these essential components, which are critical in the formulation of various medications. With a focus on delivering high-quality APIs, PolyPeptide plays a significant role in the pharmaceutical supply chain, providing expertise and resources that enable its clients to bring their products to market efficiently and effectively.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (16.10.2025):

PolyPeptide Group Ltd reported its financial results for the full year 2024, demonstrating significant improvements in revenue, gross profit, and a reduction in net loss compared to the previous year.

Revenue Growth

Revenue increased to €336.8 million in 2024, up from €320.4 million in 2023, reflecting the company's expanding market presence and increased sales.

Improved Gross Profit

The gross profit surged to €39.3 million in 2024, a substantial rise from €9.1 million in 2023, indicating enhanced operational efficiency and cost management.

Reduction in Net Loss

Net loss attributable to shareholders decreased to €19.6 million in 2024, compared to €51.4 million in 2023, showcasing the company's progress towards financial stability.

Enhanced Earnings Per Share

Earnings per share improved to -€0.59 in 2024 from -€1.56 in 2023, reflecting the company's efforts to mitigate losses and improve shareholder value.

Summarized from source with an LLMView Source

Key figures

-12.2%1Y

-32.2%3Y

%5Y

Performance

53.4%1Y

55.5%3Y

60.9%5Y

Volatility

969 M

Market cap (USD)

45,006

Daily traded volume (Shares)

29.45 / 28.75

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

0.00

0 votes

Performance:

0.00

Innovation:

0.00

Society:

0.00

Nature:

0.00

EQUITIES OF THE SAME SECTOR

Dermapharm Holding SE

Dermapharm Holding SE Valor: 40166352

Annual Return

-50%0%+50%

Risk level

110

0.42%EUR 35.45

Straumann Holding Ltd

Straumann Holding Ltd Valor: 117544866

Annual Return

-50%0%+50%

Risk level

110

-0.60%CHF 95.34

Tecan Group Ltd.

Tecan Group Ltd. Valor: 1210019

Annual Return

-50%0%+50%

Risk level

110

-0.30%CHF 133.00

Siegfried Holding Ltd

Siegfried Holding Ltd Valor: 1428449

Annual Return

-50%0%+50%

Risk level

110

1.59%CHF 70.10

COSMO Pharmaceuticals N.V.

COSMO Pharmaceuticals N.V. Valor: 32590356

Annual Return

-50%0%+50%

Risk level

110

1.97%CHF 67.40

medmix Ltd

medmix Ltd Valor: 112967710

Annual Return

-50%0%+50%

Risk level

110

-0.83%CHF 8.34

Fagron SA

Fagron SA Valor: 3425437

Annual Return

-50%0%+50%

Risk level

110

0.74%EUR 20.50

Coloplast A/S

Coloplast A/S Valor: 20259063

Annual Return

-50%0%+50%

Risk level

110

1.12%DKK 577.00

Ardent Health Partners Inc

Ardent Health Partners Inc Valor: 136301364

Annual Return

-50%0%+50%

Risk level

110

0.12%USD 8.64

Alk-Abello A/S

Alk-Abello A/S Valor: 117689788

Annual Return

-50%0%+50%

Risk level

110

-0.43%DKK 232.20

SIX

FactSet

Clearbit

Logos provided by Clearbit